Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4127-4137

  Cruciani, Mario ^a   Malena, Marina ^a   Bosco, Oliviero ^a   Nardi, Stefano ^a   Serpelloni, Giovanni ^a   Mengoli, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CYTARABINE; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; MACROLIDE; QUINOLONE DERIVATIVE;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; HUMAN; INFECTION RISK; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; MICROBIOLOGY; NEOPLASM;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MACROLIDES; NEOPLASMS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0642378131     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.234     Document Type: Article

References (65)

1. Cruciani M, Rampazzo R, Malena M, et al: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 23:795-805, 1996
2. Rotstein C, Mandell LA, Goldberg N: Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: A meta-analysis. Curr Opin Oncol 4:S2-S7, 1997 (suppl 2)
3. Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 16:1179-1187, 1998
4. Kern WV, Andrioff E, Oethinger M, et al: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681-687, 1994
5. Cometta A, Calandra T, Bille J, et al: Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240-1241, 1994 (letter)
6. Carratala J, Fernandez-Sevilla A, Tubau F: Emergence of quinolone-resistant Escherichia coli in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557-560, 1995
7. Oppheneim BA, Hartley JE, Lee W, et al: Outbreak of coagulase-negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. BMJ 299:294-297, 1989
8. Kotilainen P, Nikoskelainen J, Huovinen P: Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 161:41-44, 1990
9. Bochud PY, Eggiman Ph, Calandra Th, et al: Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31, 1994
10. Tunkel AR, Sepkowitz KA: Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34:1524-1529, 2002
11. Rozenberg-Arska M, Dekker A, Verdonch L, et al: Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin. Infection 17:240-244, 1989
12. Wimperis JZ, Baglin TP, Marcus RE, et al: An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant 8:363-367, 1991
13. Fanci R, Leoni F, Bosi A, et al: Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin vs ciprofloxacin plus amoxicillin. J Chemother 5:119-123, 1993
14. Kern WV, Hay B, Kern P, et al: A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 38:465-472, 1994
15. Broun ER, Wheat JL, Kneebone P, et al: Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 38:576-579, 1994
16. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 272:1183-1189, 1994
17. Bow EJ, Mandell LA, Louie TJ, et al: Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 125:183-190, 1996
18. Hidalgo M, Hornedo J, Lumbreras C, et al: Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother 41:1175-1177, 1997
19. Ford CD, Reilly W, Wood J, et al: Oral antimicrobial prophylaxis in bone marrow transplant recipients: Randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin. Antimicrob Agents Chemother 42:1402-1405, 1998
20. Gomez-Martin C, Sola C, Hornedo J, et al: Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial. J Clin Oncol 18:2126-2134, 2000
21. Thomas X, Troncy J, Belhabri A, et al: Interet d'associer la vancomycine a la pefloxacine en decontamination digestive pour la prevention des infections après chimioterapie aplasiante. Presse Med 29:1745-1751, 2000
22. Munoz L, Martino R, Subirà M, et al: Intensified prophylaxis of febrile neutropenia with ofloxacin plus rifampin during severe short-duration neutropenia in patients with lymphoma. Leuk Lymphoma 34:585-589, 1999
23. Archimbaud E, Guyotat D, Maupas J, et al: Pefloxacin and vancomycine vs. gentamicin, colistin sulphate and vancomycine for prevention of infections in granulocytopenic patients: A randomized double-blind study. Eur J Cancer 27:174-178, 1991
24. Gluckman E, Roudet C, Hirsch I, et al: Prophylaxis of bacterial infections after bone marrow transplantation: A randomized prospective study comparing oral broad spectrum nonabsorbable antibiotic (vancomycin-tobramycin- colistin) to absorbable antibiotics (ofloxacin-amoxicillin). Chemotherapy 37:33-38, 1991 (suppl 1)
25. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al: Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359-1368, 2001
26. Lee DG, Choi SM, Choi JH, et al: Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: A prospective randomized trial. Korean J Intern Med 17:38-44, 2002
27. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996
28. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
29. Woolf B: On estimating the relation between blood group and disease. Ann Human Genet 19:251-253, 1955
30. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
31. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728-1733, 1988
32. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997
33. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
34. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463, 2000
35. Rosenthal R: The "file-drawer problem" and tolerance for null results. Psychol Bull 86:638-641, 1979
36. Klein S, Simes J, Blackburn GL: Total parenteral nutrition and cancer clinical trials. Cancer 58:1378-1386, 1986
37. Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
38. Klastersky J: Chemoprophylaxis of Gram-negative infections in neutropenic patients. Eur Urol 17:40-45, 1990 (suppl 1)
39. Elting LS, Bodey GP, Keefe BH: Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factor. Clin Infect Dis 14:1201-1207, 1992
40. Marron A, Carratala J, Gonzalez-Barca E, et al: Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 31:1126-1130, 2000
41. Carratala J, Alcaide F, Fernandez-Sevila A, et al: Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer. Clin Infect Dis 20:1169-1173, 1995
42. Marron A, Carratala J, Alcaide F, et al: High rates of resistance to cephalosporins among viridans-group streptococci causing bacteremia in neutropenic cancer patients. J Antimicrob Chemother 47:87-91, 2001
43. Doern GV, Ferraro MJ, Brueggemann AB, et al: Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891-894, 1996
44. Kern W, Linzmeier K, Kurrie E: Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 17:396-397, 1989
45. McWhinney PHM, Patel S, Whiley RA, et al: Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 37:2493-2495, 1993
46. Razonable RR, Litzow MR, Khaliq Y, et al: Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469-1474, 2002
47. Guglielmo BJ, Graff L, Linker C, et al: Emergence of fluoroquinolone- resistant viridans streptococci associated with levofloxacin prophylaxis in neutropenic cancer patients. Presented at the Infectious Diseases Society of America 40th Annual Meeting, Chicago, IL, October 24-27, 2002 (abstr 19)
48. Jones RN, Pfaller MA: Potencies of newer fluoroquinolones against viridans group Streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! Antimicrob Agents Chemother 44:2922-2923, 2000
49. Kaneko A, Sasaki J, Shimadzu M, et al: Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother 45:771-775, 2000
50. Hooper DC: Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 32:S9-S15, 2001 (suppl 1)
51. Attal M, Schlaifer D, Rubie H, et al: Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: A prospective, randomized trial. J Clin Oncol 9:865-870, 1991
52. Teinturier C, Hartmann O, Lemerle J, et al: Prevention of gram-positive infections in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomized controlled trial of vancomycin. Pediatr Hematol Oncol 12:73-77, 1995
53. de Jong P, de Jong M, Kuijper E, et al: Evaluation of penicillin G in the prevention of streptococcal septicaemia in patients with acute myeloid leukaemia undergoing cytotoxic chemotherapy. Eur J Clin Microbiol Infect Dis 12:750-755, 1993
54. Guiot HF, Peters WG, van den Broek PJ, et al: Respiratory failure elicited by streptococcal septicaemia in patients treated with cytosine arabinoside, and its prevention by penicillin. Infection 18:131-137, 1990
55. Gilbert C, Meisenberg B, Vredenburgh J, et al: Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 12:1005-1011, 1994
56. Meisenberg B, Gollard R, Brehm T, et al: Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Support Care Cancer 4:364-369, 1996
57. Hidalgo M, Hornedo J, Trigo JM, et al: Ciprofloxacin and rifampicin vs ciprofloxacin alone in the prophylaxis of infection in solid tumor patients undergoing high dose chemotherapy and autologous peripheral blood stem cell transplantation: Results of a prospective randomized trial. Proc Am Soc Clin Oncol 15:A, 1996 (abstr 1989)
58. Bilgrami S, Feingold JM, Dorsky D, et al: Streptococcus bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 21:591-595, 1998
59. Pater JL, Weir L: Reporting the results of randomized trials of empiric antibiotic therapy in febrile neutropenic patients: A critical survey. J Clin Oncol 4:346-352, 1986
60. Immunocompromised Host Society: The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: Report of a consensus panel. J Infect Dis 161:397-401, 1990
61. Feld R, Paesmans M, Freifeld AG, et al: Methodology for clinical trials involving patients with cancer who have febrile neutropenia: Updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 35:1463-1468, 2002
62. Delarive P, Baumgarter JD, Glauser MP, et al: Evaluation de la prophylaxie antibiotique chez les patients neutropeniques avec hemopathie maligne. Schweiz Med Wonchenschr Suppl 130:1837-1844, 2000
63. De Bock R, Cometta A, Kern W, et al: Incidence of single agent gram-negative bacteremias in neutropenic cancer patients in EORTC-IATG trials of empirical therapy for febrile neutropenia. Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001 (abstr L-773)
64. O'Grady NP, Alexander M, Dellinger EP, et al: Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 35:1281-1307, 2002
65. Spanik S, Trupl J, Kunova, et al: Viridans streptococcal bacteremia due to penicillin-resistant and penicillin-sensitive streptococci: Analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Scand J Infect Dis 29:245-249, 1997